Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesenchymal Stem Cells on Immune Modulation in Living Related Kidney Transplant Patients
NCT02409940Phase 1Unknown
- Sponsor
- Post Graduate Institute of Medical Education and Research
- Start
- Sep 2013
- Primary completion
- Sep 2016
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of mesenchymal stem cells in renal transplant rejection (RTR) (3 arms), sponsored by Post Graduate Institute of Medical Education and Research. Primary endpoints: Expansion of regulatory T cell compartment at 6 months and Normalization of serum creatinine levels at 6 months. Status: unknown.
02
Drugs
mesenchymal stem cells
03
Conditions
renal transplant rejection (RTR)
Beyond the preview
Go deeper on NCT02409940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02409940.